[go: up one dir, main page]

WO2014057436A3 - Anticancer conjugate - Google Patents

Anticancer conjugate Download PDF

Info

Publication number
WO2014057436A3
WO2014057436A3 PCT/IB2013/059234 IB2013059234W WO2014057436A3 WO 2014057436 A3 WO2014057436 A3 WO 2014057436A3 IB 2013059234 W IB2013059234 W IB 2013059234W WO 2014057436 A3 WO2014057436 A3 WO 2014057436A3
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
conjugate
domain
fusion protein
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/059234
Other languages
French (fr)
Other versions
WO2014057436A2 (en
Inventor
Jerzy Szczepan Pieczykolan
Zbigniew Majka
Wojciech STROŻEK
Marlena Maria GAŁĄZKA
Krzysztof Kazimierz Lemke
Anna Maria PIECZYKOLAN
Katarzyna Dorota WICIEJOWSKA
Joanna Adriana JASZCZEWSKA
Przemysław ZIEMKOWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adamed Sp zoo
Original Assignee
Adamed Sp zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp zoo filed Critical Adamed Sp zoo
Publication of WO2014057436A2 publication Critical patent/WO2014057436A2/en
Publication of WO2014057436A3 publication Critical patent/WO2014057436A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A conjugate comprises a fusion protein comprising domain (a), which is the functional fragment of a hTRAIL protein sequence, said fragment beginning with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is the sequence of an immunostimulating effector peptide; and the molecule of a chemical compound Z with antiblastic activity, which is linked to the fusion protein directly or by means ofa conjugation linker L. the conjugate is useful in the treatment of cancer diseases.
PCT/IB2013/059234 2012-10-10 2013-10-09 Anticancer conjugate Ceased WO2014057436A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLPL401144 2012-10-10
PL40114412 2012-10-10

Publications (2)

Publication Number Publication Date
WO2014057436A2 WO2014057436A2 (en) 2014-04-17
WO2014057436A3 true WO2014057436A3 (en) 2014-05-30

Family

ID=49780116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059234 Ceased WO2014057436A2 (en) 2012-10-10 2013-10-09 Anticancer conjugate

Country Status (1)

Country Link
WO (1) WO2014057436A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) * 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
JP6772549B2 (en) * 2016-05-23 2020-10-21 Dic株式会社 Polymerizable compounds and optical anisotropics
CN111051329B (en) * 2017-08-10 2024-07-30 住友制药株式会社 Hamiltelin derivatives and their antibody drug complexes
FI3666787T3 (en) * 2017-08-10 2024-03-15 Sumitomo Pharma Co Ltd Antibody-drug conjugates containing a hemiasterlin derivative
JP7560255B2 (en) * 2019-02-13 2024-10-02 住友ファーマ株式会社 Medicine containing antibody-drug conjugate containing hemiasterlin derivative
EP3925668A4 (en) * 2019-02-13 2022-11-09 Sumitomo Pharma Co., Ltd. HEMIASTERLINE DERIVATIVE HAVING A CYSTEINE RESIDUE
JP7479302B2 (en) * 2019-02-13 2024-05-08 住友ファーマ株式会社 Hemiasterlin derivatives and their antibody-drug conjugates
JP2022529212A (en) * 2019-04-02 2022-06-20 ベナトルクス ファーマシューティカルズ，インク． Solid form of beta-lactamase inhibitor delivered orally and its use
CN112851647B (en) * 2019-11-28 2023-01-13 中国海洋大学 Brefeldin A derivative and preparation method and application thereof
CN111285828B (en) * 2020-03-11 2022-02-18 中国科学院南海海洋研究所 Compound proximicin and its preparation method and application
CN112125918B (en) * 2020-07-16 2021-10-01 中国科学院南海海洋研究所 Aromatic polyketone compounds Talaromyoxaones A and B and preparation method and application thereof
CN115304597B (en) * 2022-08-22 2023-10-20 中国科学院深圳先进技术研究院 Beta-carboline compounds and application thereof in preparation of medicines for treating or preventing tumor diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043900A1 (en) * 2007-10-03 2009-04-09 Covalys Biosciences Ag Drug transfer based on coenzyme a and acyl carrier protein
US20090162290A1 (en) * 2005-09-09 2009-06-25 Therapharm Gmbh Method for the synthesis of penta-pendant enantiomer-pure chelators and process for therapeutically active bioconjugates preparation by a covalent binding thereof
WO2012072815A1 (en) * 2010-12-03 2012-06-07 Adamed Sp. Z O.O. Anticancer fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04334377A (en) 1990-12-31 1992-11-20 Akzo Nv Acid-instable linker molecule
DE10310082A1 (en) 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-binding doxorubicin peptide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162290A1 (en) * 2005-09-09 2009-06-25 Therapharm Gmbh Method for the synthesis of penta-pendant enantiomer-pure chelators and process for therapeutically active bioconjugates preparation by a covalent binding thereof
WO2009043900A1 (en) * 2007-10-03 2009-04-09 Covalys Biosciences Ag Drug transfer based on coenzyme a and acyl carrier protein
WO2012072815A1 (en) * 2010-12-03 2012-06-07 Adamed Sp. Z O.O. Anticancer fusion protein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JINPING L ET AL: "Analysis of monoclonal antibody and immunoconjugate digests by capillary electrophoresis and capillary liquid chromatography", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V, NL, vol. 735, no. 1, 31 May 1996 (1996-05-31), pages 357 - 366, XP004039030, ISSN: 0021-9673, DOI: 10.1016/0021-9673(95)01054-8 *
JULIA STIEGLMAIER ET AL: "Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 2, 31 July 2007 (2007-07-31), pages 233 - 246, XP019561073, ISSN: 1432-0851, DOI: 10.1007/S00262-007-0370-8 *
KREITMAN ROBERT J: "Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies", BIODRUGS: CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY, ADIS INTERNATIONAL, FR, vol. 23, no. 1, 1 January 2009 (2009-01-01), pages 1 - 13, XP002711759, ISSN: 1173-8804, DOI: 10.2165/00063030-200923010-00001 *
SHIN J N ET AL: "Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 312, no. 19, 15 November 2006 (2006-11-15), pages 3892 - 3898, XP024945270, ISSN: 0014-4827, [retrieved on 20061115], DOI: 10.1016/J.YEXCR.2006.08.015 *
TEN CATE B ET AL: "A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability", August 2009, LEUKEMIA (BASINGSTOKE), VOL. 23, NR. 8, PAGE(S) 1389-1397, ISSN: 0887-6924, XP002719935 *

Also Published As

Publication number Publication date
WO2014057436A2 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
WO2014057436A3 (en) Anticancer conjugate
WO2013080147A3 (en) Anticancer fusion protein
MX2023010178A (en) Anti-cd70 antibody drug conjugates.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
WO2015053871A8 (en) NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
CY1120637T1 (en) CD40 COMPETITIVE POLYPEPTIDE ANTIBODIES
PH12013500714A1 (en) Anticancer fusion protein
NZ703585A (en) Blood brain barrier shuttle
BR112015023418A2 (en) antibody and drug conjugate, antibody or antigen binding fragment, their production processes, their uses, nucleic acid, vector, and host cell
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
NZ607710A (en) 4-1bb binding molecules
MX2015005124A (en) Drug-protein conjugates.
PH12013500715A1 (en) Anticancer fusion protein
WO2013098755A3 (en) Anticancer fusion protein
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
WO2011135222A3 (en) Use of peptides as transporters intended for the internalization of molecules of interest into target cells
WO2012143477A3 (en) Anticancer fusion protein
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
MX2013003168A (en) Anti-ephrin-b2 antibody and use thereof.
MX2013010688A (en) New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids.
TH147042A (en) Conjugated molecules A new combination of peptides derived from CD4 receptors that are coupled with poly anionic polypeptides. For the treatment of AIDS
WO2018080396A3 (en) Compounds and methods to target a molecule to a specific cellular location
WO2013125988A3 (en) Single-domain antibody specifically binding to s100a4/mts1 protein and use of said antibody to detect said protein
TH146212A (en) Antigen-binding proteins and their use as a solution for cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13808226

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13808226

Country of ref document: EP

Kind code of ref document: A2